Ulomiris® (ravulizumab-cwvz) (Intravenous)

I. Length of Authorization

Coverage will be provided for twelve (12) months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Ulomiris 10 mg/mL** – 30 mL SDV: 10 vials on day zero followed by 13 vials starting on day 14 and every 8 weeks thereafter
- Ulomiris 100 mg/mL – 3 mL SDV: 10 vials on day zero followed by 13 vials starting on day 14 and every 8 weeks thereafter
- Ulomiris 100 mg/mL – 11 mL SDV: 3 vials on day zero followed by 3 vials starting on day 14 and every 8 weeks thereafter

B. Max Units (per dose and over time) [HCPCS Unit]:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Loading Dose Units</th>
<th>Maintenance Dose Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>PNH/aHUS</td>
<td>300 units on Day 0</td>
<td>360 units on Day 14 and every 8 weeks thereafter</td>
</tr>
</tbody>
</table>

III. Initial Approval Criteria ¹

Site of care specialty infusion program requirements are met (refer to Moda Site of Care Policy).

Coverage is provided in the following conditions:

- Patient is at least 1 month of age: AND
- Prescriber is enrolled in the Ulomiris Risk Evaluation and Mitigation Strategy (REMS) program: AND

Universal Criteria ¹

- Patients must be administered a meningococcal vaccine at least two weeks prior to initiation of therapy and will continue to be revaccinated according to current medical guidelines for vaccine use *(If urgent Ulomiris therapy is indicated in an unvaccinated
patient, administer meningococcal vaccine(s) as soon as possible and provide patients with two weeks of antibacterial drug prophylaxis.): **AND**

- Will not be used in combination with other complement-inhibitor therapy (i.e., eculizumab, pegcetacoplan): **AND**

**Paroxysmal Nocturnal Hemoglobinuria (PNH) † Φ ¹,₄,₈,⁹**

- Used as switch therapy: **AND**
  
  o Patient is currently receiving treatment with Soliris and has shown a beneficial disease response and absence of unacceptable toxicity while on therapy: **OR**
  
  o Patient is complement inhibitor treatment-naïve: **AND**

  - Diagnosis must be accompanied by detection of PNH clones of at least 5% by flow cytometry diagnostic testing: **AND**
    
    ▪ Demonstrate the presence of at least 2 different glycosylphosphatidylinositol (GPI) protein deficiencies (e.g., CD55, CD59, etc.) within at least 2 different cell lines (e.g., granulocytes, monocytes, erythrocytes): **AND**
    
    ▪ Patient has laboratory evidence of significant intravascular hemolysis (i.e., LDH ≥1.5 x ULN) and at least one other indication for therapy from the following:
      
      – Presence of a thrombotic event
      
      – Presence of organ damage secondary to chronic hemolysis (i.e., renal insufficiency, pulmonary insufficiency or hypertension)
      
      – Patient is pregnant and potential benefit outweighs potential fetal risk
      
      – Patient has symptomatic anemia (regardless of transfusion dependence)
      
      – Patient has disabling fatigue
      
      – Patient has abdominal pain requiring admission or opioid analgesia: **AND**

    ▪ Documented baseline values for one or more of the following (necessary for renewal): serum lactate dehydrogenase (LDH), hemoglobin level, and packed RBC transfusion requirement, history of thrombotic events

**Atypical Hemolytic Uremic Syndrome (aHUS) † ¹,₅,⁷**

- Used as switch therapy: **AND**
  
  o Patient is currently receiving treatment with Soliris and has shown a beneficial disease response and absence of unacceptable toxicity while on therapy: **OR**
  
  o Patient is complement inhibitor treatment-naïve: **AND**
Patient shows signs of thrombotic microangiopathy (TMA) (e.g., changes in mental status, seizures, angina, dyspnea, thrombosis, increasing blood pressure, decreased platelet count, increased serum creatinine, increased LDH, etc.): **AND**

- Thrombotic Thrombocytopenic Purpura (TTP) has been ruled out by evaluating ADAMTS-13 level (ADAMTS-13 activity level ≥ 10%): **AND**
- Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS) has been ruled out: **AND**
- Other causes have been ruled out such as coexisting diseases or conditions (e.g., bone marrow transplantation, solid organ transplantation, malignancy, autoimmune disorder, drug-induced, etc.) or known genetic defect in cobalamin C metabolism: **AND**
- Documented baseline values for one or more of the following (necessary for renewal): serum lactate dehydrogenase (LDH), serum creatinine/eGFR, platelet count, and dialysis requirement

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ø Orphan Drug

### IV. Renewal Criteria

Coverage may be renewed based upon the following criteria:

- **Patient continues to meet the universal and other indication-specific relevant criteria identified in section III: AND**
- **Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include:** serious meningococcal infections (septicemia and/or meningitis), infusion-related reactions, other serious infections (i.e., *Streptococcus pneumoniae, Haemophilus influenzae, Neisseria gonorrhoeae*), thrombotic microangiopathy (TMA) complications, etc.: **AND**
- **Disease response indicated by one or more of the following:**
  - **PNH**<sup>1,4,8</sup>
    - Decrease in serum LDH from pretreatment baseline
    - Stabilization/improvement in hemoglobin level from pretreatment baseline
    - Decrease in packed RBC transfusion requirement from pretreatment baseline
    - Reduction in thromboembolic events
  - **aHUS**<sup>1,5,7</sup>
    - Decrease in serum LDH from pretreatment baseline
    - Stabilization/improvement in serum creatinine/eGFR from pretreatment baseline
    - Increase in platelet count from pretreatment baseline
    - Patient no longer requires dialysis treatments

**Switch therapy from Soliris to Ultomiris**
• Refer to Section III for criteria

V. Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complement-Inhibitor Therapy Naive*</td>
<td></td>
</tr>
<tr>
<td>Administer the doses based on the patient’s body weight. Starting 2 weeks after the loading dose, begin maintenance doses once every 4 weeks or every 8 weeks (depending on body weight)</td>
<td></td>
</tr>
<tr>
<td><strong>Body Weight Range</strong></td>
<td><strong>Loading Dose (mg)</strong></td>
</tr>
<tr>
<td>≥5 kg - &lt;10 kg</td>
<td>600</td>
</tr>
<tr>
<td>≥10 kg - &lt;20 kg</td>
<td>600</td>
</tr>
<tr>
<td>≥20 kg - &lt;30 kg</td>
<td>900</td>
</tr>
<tr>
<td>≥30 kg - &lt;40 kg</td>
<td>1,200</td>
</tr>
<tr>
<td>≥40 kg - &lt;60 kg</td>
<td>2,400</td>
</tr>
<tr>
<td>≥60 kg - &lt;100 kg</td>
<td>2,700</td>
</tr>
<tr>
<td>≥100 kg</td>
<td>3,000</td>
</tr>
</tbody>
</table>

*Note: for Soliris switch therapy please refer to the package insert for appropriate switch dosing.

VI. Billing Code/Availability Information

**Note: This NDC has been discontinued as of 06/11/2021.**

HCPCS Code:

- J1303 – Injection, ravulizumab-cwvz, 10 mg; 1 billable unit = 10 mg

NDC(s):

- Ultomiris 300 mg/3 mL single-use vials for injection: 25682-0025-xx
- Ultomiris 300 mg/30 mL single-use vials for injection: 25682-0022-xx**
- Ultomiris 1100 mg/11 mL single-use vials for injection: 25682-0028-xx

VII. References


Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D59.3</td>
<td>Hemolytic-uremic syndrome</td>
</tr>
<tr>
<td>D59.5</td>
<td>Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]</td>
</tr>
</tbody>
</table>

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>Jurisdiction</td>
<td>Applicable State/US Territory</td>
<td>Contractor</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, LLC</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>